
David J Kuter

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6154527/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood, 2020, 136, 489-500.	0.6	1,021
2	Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet, The, 2008, 371, 395-403.	6.3	784
3	American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Advances, 2019, 3, 3829-3866.	2.5	684
4	Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood, 2001, 98, 3241-3248.	0.6	658
5	Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Advances, 2019, 3, 3780-3817.	2.5	593
6	Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia. New England Journal of Medicine, 2010, 363, 1889-1899.	13.9	374
7	Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood, 2002, 100, 3457-3469.	0.6	351
8	New thrombopoietic growth factors. Blood, 2007, 109, 4607-4616.	0.6	312
9	Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting. Blood Reviews, 2020, 41, 100648.	2.8	267
10	Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres. British Journal of Haematology, 2007, 139, 351-362.	1.2	249
11	Longâ€ŧerm treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. British Journal of Haematology, 2013, 161, 411-423.	1.2	234
12	Thrombotic Complications of Central Venous Catheters in Cancer Patients. Oncologist, 2004, 9, 207-216.	1.9	213
13	The biology of thrombopoietin and thrombopoietin receptor agonists. International Journal of Hematology, 2013, 98, 10-23.	0.7	197
14	Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim. Blood, 2009, 114, 3748-3756.	0.6	177
15	Thrombopoietin and Thrombopoietin Mimetics in the Treatment of Thrombocytopenia. Annual Review of Medicine, 2009, 60, 193-206.	5.0	164
16	The mechanism of apoptosis in human platelets during storage. Transfusion, 2000, 40, 1320-1329.	0.8	156
17	Interaction of thrombopoietin with the platelet c-mpl receptor in plasma: binding, internalization, stability and pharmacokinetics. British Journal of Haematology, 1999, 106, 345-356.	1.2	147
18	Hereditary hemorrhagic telangiectasia: diagnosis and management from the hematologist's perspective. Haematologica, 2018, 103, 1433-1443.	1.7	123

#	Article	IF	CITATIONS
19	A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia. Blood, 2014, 123, 3887-3894.	0.6	112
20	The Physiology of Platelet Production. Stem Cells, 1996, 14, 88-101.	1.4	111
21	Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia. American Journal of Hematology, 2020, 95, 178-187.	2.0	99
22	New Thrombopoietic Growth Factors. Clinical Lymphoma and Myeloma, 2009, 9, S347-S356.	1.4	95
23	Biology and Chemistry of Thrombopoietic Agents. Seminars in Hematology, 2010, 47, 243-248.	1.8	93
24	Thrombopoietin therapy increases platelet yields in healthy platelet donors. Blood, 2001, 98, 1339-1345.	0.6	89
25	Milestones in understanding platelet production: a historical overview. British Journal of Haematology, 2014, 165, 248-258.	1.2	85
26	Exacerbation of immune thrombocytopenia following COVIDâ€19 vaccination. British Journal of Haematology, 2021, 195, 365-370.	1.2	72
27	Thrombopoietin levels in patients with disorders of platelet production: Diagnostic potential and utility in predicting response to TPO Receptor agonists. American Journal of Hematology, 2013, 88, 1041-1044.	2.0	70
28	Healthâ€related quality of life in nonsplenectomized immune thrombocytopenia patients receiving romiplostim or medical standard of care. American Journal of Hematology, 2012, 87, 558-561.	2.0	68
29	Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia. Therapeutic Advances in Hematology, 2019, 10, 204062071984173.	1.1	65
30	An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study. Haematologica, 2021, 106, 2161-2169.	1.7	64
31	Thrombopoietin and Platelet Production in Chronic Immune Thrombocytopenia. Hematology/Oncology Clinics of North America, 2009, 23, 1193-1211.	0.9	60
32	Miglustat therapy in type 1 Gaucher disease: Clinical and safety outcomes in a multicenter retrospective cohort study. Blood Cells, Molecules, and Diseases, 2013, 51, 116-124.	0.6	60
33	A modern reassessment of glycoprotein-specific direct platelet autoantibody testing in immune thrombocytopenia. Blood Advances, 2020, 4, 9-18.	2.5	56
34	Thrombopoietin level predicts response to treatment with eltrombopag and romiplostim in immune thrombocytopenia. American Journal of Hematology, 2018, 93, 1501-1508.	2.0	55
35	Addressing the diagnostic gaps in pyruvate kinase deficiency: Consensus recommendations on the diagnosis of pyruvate kinase deficiency. American Journal of Hematology, 2019, 94, 149-161.	2.0	55
36	SARS-CoV-2 vaccination and ITP in patients with de novo or preexisting ITP. Blood, 2022, 139, 1564-1574.	0.6	55

#	Article	IF	CITATIONS
37	Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia. New England Journal of Medicine, 2022, 386, 1421-1431.	13.9	52
38	Exploring the patient journey to diagnosis of Gaucher disease from the perspective of 212 patients with Gaucher disease and 16 Gaucher expert physicians. Molecular Genetics and Metabolism, 2017, 122, 122-129.	0.5	51
39	The use of romiplostim in treating chemotherapy-induced thrombocytopenia in patients with solid tumors. Haematologica, 2018, 103, e169-e172.	1.7	51
40	Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim. International Journal of Hematology, 2015, 101, 255-263.	0.7	49
41	Clinical outcomes in a cohort of patients with heparinâ€induced thrombocytopenia. American Journal of Hematology, 2017, 92, 730-738.	2.0	49
42	Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia (<scp>ITP</scp>) for up to 1Âyear and in those with chronic <scp>ITP</scp> for more than 1Âyear: a subgroup analysis of integrated data from completed romiplostim studies. British Journal of Haematology, 2019, 185, 503-513.	1.2	49
43	Immune Thrombocytopenia in Adults: Modern Approaches to Diagnosis and Treatment. Seminars in Thrombosis and Hemostasis, 2020, 46, 275-288.	1.5	49
44	A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies. Haematologica, 2021, 106, 1148-1157.	1.7	49
45	Cancer, Coagulation, and Anticoagulation. Oncologist, 1999, 4, 443-449.	1.9	48
46	The End Is Just the Beginning: Megakaryocyte Apoptosis and Platelet Release. International Journal of Hematology, 2001, 74, 365-374.	0.7	45
47	Efficacy and safety of givosiran for acute hepatic porphyria: 24â€month interim analysis of the randomized phase 3 ENVISION study. Liver International, 2022, 42, 161-172.	1.9	41
48	Presenting signs and patient coâ€variables in Gaucher disease: outcome of the Gaucher Earlier Diagnosis Consensus (GED) Delphi initiative. Internal Medicine Journal, 2019, 49, 578-591.	0.5	39
49	New drugs for familiar therapeutic targets: thrombopoietin receptor agonists and immune thrombocytopenic purpura. European Journal of Haematology, 2008, 80, 9-18.	1.1	38
50	Hepatocellular carcinoma in Gaucher disease: an international case series. Journal of Inherited Metabolic Disease, 2018, 41, 819-827.	1.7	37
51	Romiplostim for the management of perioperative thrombocytopenia. British Journal of Haematology, 2018, 182, 106-113.	1.2	37
52	Phase II Trial of Single Agent Bortezomib (VELCADE®) in Patients with Previously Untreated Multiple Myeloma (MM) Blood, 2004, 104, 336-336.	0.6	36
53	Platelet aggregation response in immune thrombocytopenia patients treated with romiplostim. Annals of Hematology, 2019, 98, 581-588.	0.8	34
54	Apheresis platelets: Emerging issues related to donor platelet count, apheresis platelet yield, and platelet transfusion dose. Journal of Clinical Apheresis, 1998, 13, 114-119.	0.7	31

#	Article	lF	CITATIONS
55	Thrombopoietin: Biology and Clinical Applications. Oncologist, 1996, 1, 98-106.	1.9	29
56	Romiplostim. Cancer Treatment and Research, 2010, 157, 267-288.	0.2	28
57	The platelet thrombopoietin receptor number and function are markedly decreased in patients with essential thrombocythaemia. British Journal of Haematology, 2000, 111, 943-953.	1.2	27
58	Relative potency of the thrombopoietin receptor agonists eltrombopag, avatrombopag and romiplostim in a patient with chronic immune thrombocytopenia. British Journal of Haematology, 2018, 183, 168-168.	1.2	26
59	Characterization of the rate, predictors, and thrombotic complications of thrombocytosis in iron deficiency anemia. American Journal of Hematology, 2020, 95, 1180-1186.	2.0	26
60	Romiplostim in the management of the thrombocytopenic surgical patient. Transfusion, 2015, 55, 2505-2510.	0.8	24
61	An alternative intermittent eltrombopag dosing protocol for the treatment of chronic immune thrombocytopenia. British Journal of Clinical Pharmacology, 2018, 84, 2673-2677.	1.1	24
62	Markers of autoimmunity in immune thrombocytopenia: prevalence and prognostic significance. Blood Advances, 2019, 3, 3515-3521.	2.5	24
63	Evaluation of the prothrombin fragment 1.2 in patients with coronavirus disease 2019 (<scp>COVID</scp> â€19). American Journal of Hematology, 2020, 95, 1479-1485.	2.0	24
64	Fondaparinux in the Treatment of Heparin-Induced Thrombocytopenia Blood, 2004, 104, 1775-1775.	0.6	23
65	Avatrombopag, an oral thrombopoietin receptor agonist: results of two doubleâ€blind, doseâ€rising, placeboâ€controlled Phase 1 studies. British Journal of Haematology, 2018, 183, 466-478.	1.2	22
66	Apoptosis in Platelets During Ex Vivo Storage. Vox Sanguinis, 2002, 83, 311-313.	0.7	21
67	Remissions after long-term use of romiplostim for immune thrombocytopenia. Haematologica, 2016, 101, e476-e478.	1.7	21
68	The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag. Blood Reviews, 2022, 53, 100909.	2.8	21
69	The use of PEG‐rHuMGDF in platelet apheresis. Stem Cells, 1998, 16, 231-242.	1.4	19
70	The role of romiplostim for pediatric patients with immune thrombocytopenia. Therapeutic Advances in Hematology, 2020, 11, 204062072091299.	1.1	19
71	An evaluation of avatrombopag for the treatment of thrombocytopenia. Expert Opinion on Pharmacotherapy, 2021, 22, 273-280.	0.9	19
72	Novel therapies for immune thrombocytopenia. British Journal of Haematology, 2022, 196, 1311-1328.	1.2	19

#	Article	IF	CITATIONS
73	Fostamatinib for the treatment of warm antibody autoimmune hemolytic anemia: Phase 2, multicenter, openâ€label study. American Journal of Hematology, 2022, 97, 691-699.	2.0	19
74	Bone Marrow Reticulin in Patients with Immune Thrombocytopenic Purpura Blood, 2006, 108, 3982-3982.	0.6	18
75	Complement C1s inhibition with sutimlimab results in durable response in cold agglutinin disease: CARDINAL study 1-year interim follow-up results. Haematologica, 2022, 107, 1698-1702.	1.7	18
76	Symptom Burden and Blood Counts in Patients With Polycythemia Vera in the United States: An Analysis From the REVEAL Study. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 579-584.e1.	0.2	16
77	Pregnancy outcomes, risk factors, and cell count trends in pregnant women with essential thrombocythemia. Leukemia Research, 2020, 98, 106459.	0.4	16
78	How I treat primary ITP in adult patients who are unresponsive to or dependent on corticosteroid treatment. Blood, 2021, 137, 2736-2744.	0.6	15
79	Long-Term Efficacy and Safety of Romiplostim Treatment of Adult Patients with Chronic Immune Thrombocytopenia (ITP): Final Report from an Open-Label Extension Study. Blood, 2010, 116, 68-68.	0.6	15
80	Safety and efficacy of selfâ€administered romiplostim in patients with immune thrombocytopenia: Results of an integrated database of five clinical trials. American Journal of Hematology, 2020, 95, 643-651.	2.0	14
81	Treatment Patterns and Blood Counts in Patients With Polycythemia Vera Treated With Hydroxyurea in the United States: An Analysis From the REVEAL Study. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 219-225.	0.2	13
82	Long-Term Safety and Efficacy of Sutimlimab in Patients with Chronic Immune Thrombocytopenia. Blood, 2020, 136, 14-15.	0.6	13
83	Assessment of romiplostim immunogenicity in adult patients in clinical trials and in a global postmarketing registry. British Journal of Haematology, 2020, 190, 923-932.	1.2	12
84	Phase I/II, Open-Label, Adaptive Study of Oral Bruton Tyrosine Kinase Inhibitor PRN1008 in Patients with Relapsed/Refractory Primary or Secondary Immune Thrombocytopenia. Blood, 2019, 134, 87-87.	0.6	12
85	TPO concentrations and response to romiplostim. American Journal of Hematology, 2014, 89, 1155-1156.	2.0	11
86	What is the potential for thrombopoietic agents in acute leukemia?. Best Practice and Research in Clinical Haematology, 2011, 24, 553-558.	0.7	10
87	Romiplostim in adults with newly diagnosed or persistent immune thrombocytopenia. Expert Review of Hematology, 2020, 13, 1319-1332.	1.0	10
88	Long-Term Treatment with Romiplostim in Patients with Chronic Immune Thrombocytopenic Purpura (ITP): 3-Year Update from An Open-Label Extension Study. Blood, 2008, 112, 402-402.	0.6	10
89	Recurrence of Acute Intermittent Porphyria After Liver Transplantation. Annals of Internal Medicine, 2019, 170, 904.	2.0	9
90	Scoring system to facilitate diagnosis of Gaucher disease. Internal Medicine Journal, 2020, 50, 1538-1546.	0.5	9

#	Article	IF	CITATIONS
91	Clinical overview and practical considerations for optimizing romiplostim therapy in patients with immune thrombocytopenia. Blood Reviews, 2021, 49, 100811.	2.8	9
92	Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Results from the Phase 3 Cardinal Study. Blood, 2019, 134, LBA-2-LBA-2.	0.6	9
93	Management of disseminated intravascular coagulation in a patient with hepatic angiosarcoma. Medicine (United States), 2018, 97, e13321.	0.4	8
94	A Randomized, Double-Blind, Placebo-Controlled Phase II Trial on the Efficacy, Safety and Tolerability of E5501 (AKR501) In Subjects with Chronic Immune Thrombocytopenia (ITP). Blood, 2010, 116, 71-71.	0.6	8
95	Safety and Efficacy of PRTX-100, a Highly Purified Form of Staphylococcal Protein A, in Patients with Immune Thrombocytopenia (ITP). Blood, 2016, 128, 4929-4929.	0.6	7
96	Infections and vaccination in hereditary hemorrhagic telangiectasia: microbiological evidence-based considerations. Haematologica, 2018, 103, e492-e495.	1.7	6
97	Lactate dehydrogenase is elevated in immune thrombocytopenia and inversely correlates with platelet count. British Journal of Haematology, 2019, 187, e61-e64.	1.2	6
98	General Aspects of Thrombocytopenia, Platelet Transfusions, and Thrombopoietic Growth Factors. , 2019, , 108-126.		6
99	Thrombopoietin level predicts response to treatment with romiplostim in chemotherapyâ€induced thrombocytopenia. American Journal of Hematology, 2021, 96, 1563-1568.	2.0	6
100	Fostamatinib, a Spleen Tyrosine Kinase Inhibitor, for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia: Initial Results of the Multicenter, Open-Label Extension Period of the Soar Phase 2 Study. Blood, 2018, 132, 3612-3612.	0.6	6
101	Inhibition of the Classical Pathway of Complement with Sutimlimab in Chronic Immune Thrombocytopenic Purpura Patients without Adequate Response to Two or More Prior Therapies. Blood, 2019, 134, 898-898.	0.6	6
102	Pregnancy Outcomes, Risk Factors, and Gestational Cell Count Trends in Pregnant Women with Essential Thrombocythemia and Polycythemia Vera. Blood, 2019, 134, 4172-4172.	0.6	6
103	Oral Rilzabrutinib, a Bruton Tyrosine Kinase Inhibitor, Showed Clinically Active and Durable Platelet Responses and Was Well-Tolerated in Patients with Heavily Pretreated Immune Thrombocytopenia. Blood, 2020, 136, 13-14.	0.6	6
104	What is the role of novel thrombopoietic agents in the management of acute leukemia?. Best Practice and Research in Clinical Haematology, 2016, 29, 372-378.	0.7	5
105	Antiplatelet Antibody Testing in Immune Thrombocytopenia and Evans Syndrome: Longitudinal Serologic Evolution and Relation to Clinical Features. Blood, 2018, 132, 1137-1137.	0.6	5
106	Analysis of Mortality Rates During Romiplostim Clinical Studies of Patients (Pts) with Immune Thrombocytopenia (ITP) Blood, 2010, 116, 3701-3701.	0.6	5
107	An Ongoing, Observational Cohort Study in Multiple Myeloma (PREAMBLE): Preliminary Efficacy Analyses in Patients with 1 Line of Prior Therapy. Blood, 2016, 128, 2403-2403.	0.6	5
108	Updated Phase I/II Safety and Efficacy Results for Oral Bruton Tyrosine Kinase Inhibitor Rilzabrutinib in Patients with Relapsed/Refractory Immune Thrombocytopenia. Blood, 2021, 138, 14-14.	0.6	5

#	Article	IF	CITATIONS
109	LUNA3 Phase III Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of the Oral BTK Inhibitor Rilzabrutinib in Adults and Adolescents with Persistent or Chronic Immune Thrombocytopenia. Blood, 2021, 138, 1010-1010.	0.6	5
110	Pure White Cell Aplasia and Necrotizing Myositis. Case Reports in Hematology, 2016, 2016, 1-5.	0.3	4
111	Case 38-2020: A 52-Year-Old Man with Cancer and Acute Hypoxemia. New England Journal of Medicine, 2020, 383, 2372-2383.	13.9	4
112	Open-label, expanded access study of taliglucerase alfa in patients with Gaucher disease requiring enzyme replacement therapy. Blood Cells, Molecules, and Diseases, 2020, 82, 102418.	0.6	4
113	Iron overload after complement inhibitor treatment of Paroxysmal Nocturnal Hemoglobinuria. American Journal of Hematology, 2021, 96, E235-E237.	2.0	4
114	Eighteen-Month Interim Analysis of Efficacy and Safety of Givosiran, an RNAi Therapeutic for Acute Hepatic Porphyria, in the Envision Open Label Extension. Blood, 2020, 136, 13-13.	0.6	4
115	Fostamatinib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (wAIHA): A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Global Study. Blood, 2020, 136, 1-3.	0.6	4
116	Comparison of Splenectomy and Treatment Failure Incidence in Nonsplenectomized Patients with Immune Thrombocytopenia (ITP) Receiving Romiplostim or Medical Standard of Care: 1-Year Treatment and 6-Month Safety Follow-up Blood, 2009, 114, 679-679.	0.6	4
117	Long-Term Efficacy and Safety of Romiplostim for the Treatment of Patients with Chronic Immune Thrombocytopenia (ITP): 5-Year Update From An Open-Label Extension Study Blood, 2009, 114, 681-681.	0.6	4
118	Efficacy, Safety and Tolerability of E5501 (AKR501) In a 6-Month Extension Study In Subjects with Chronic Immune Thrombocytopenia (ITP) Blood, 2010, 116, 3695-3695.	0.6	4
119	Thrombopoietin Levels May Predict Responsiveness to Therapy with Thrombopoietin Agonists Among Patients with Immune Thrombocytopenic Purpura,. Blood, 2011, 118, 3288-3288.	0.6	4
120	In Reply: Lowâ€Dose Warfarin Prophylaxis for Catheterâ€Associated Thrombosis in Cancer Patients. Can It Be Safely Associated with 5â€Fluorouracilâ€Based Chemotherapy?. Oncologist, 2004, 9, 596-596.	1.9	3
121	Ammonia Predicts Hepatic Involvement and Pulmonary Hypertension in Patients With Hereditary Hemorrhagic Telangiectasia. Clinical and Translational Gastroenterology, 2020, 11, e00118.	1.3	3
122	Apheresis platelets: Emerging issues related to donor platelet count, apheresis platelet yield, and platelet transfusion dose. , 1998, 13, 114.		3
123	Assessment of Romiplostim Immunogenicity in Adult Patients in Clinical Trials and in a Global Registry. Blood, 2018, 132, 2427-2427.	0.6	3
124	Fostamatinib, a Spleen Tyrosine Kinase (SYK) Inhibitor, for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (wAIHA): Final Results of the Phase 2, Multicenter, Open-Label Study. Blood, 2019, 134, 3518-3518.	0.6	3
125	Daratumumab As a Treatment for Adult Immune Thrombocytopenia: A Phase II Study with Safety Run-in (the DART Study). Blood, 2021, 138, 2088-2088.	0.6	3
126	Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Interim Results of the Phase 3 Cardinal Study Long-Term Follow-up. Blood, 2020, 136, 24-25.	0.6	3

#	Article	IF	CITATIONS
127	Endogenous thrombopoietin levels are elevated following double cord blood unit transplantation. Bone Marrow Transplantation, 2020, 55, 1178-1180.	1.3	2
128	Preparing patients with immune thrombocytopenia for surgery: what are the options?. Lancet Haematology,the, 2020, 7, e626-e627.	2.2	2
129	Congenital thrombotic thrombocytopenic purpura (TTP) with placental abruption despite maternal improvement: a case report. BMC Pregnancy and Childbirth, 2020, 20, 365.	0.9	2
130	Lessons Learned Using Realâ€World Data to Emulate Randomized Trials: A Case Study of Treatment Effectiveness for Newly Diagnosed Immune Thrombocytopenia. Clinical Pharmacology and Therapeutics, 2021, 110, 1570-1578.	2.3	2
131	The Incidence of Thrombosis in Patients with Isolated Heparin Induced Thrombocytopenia Blood, 2006, 108, 1049-1049.	0.6	2
132	A Comparative Proteomic Analysis of Platelets from Healthy Human Patients and Chronic ITP Patients Receiving AMG 531, a Thrombopoiesis-Stimulating Protein Blood, 2007, 110, 1313-1313.	0.6	2
133	Romiplostim for Treatment and Prevention of Chemotherapy-Associated Thrombocytopenia. Blood, 2016, 128, 3748-3748.	0.6	2
134	Treatment Sequencing in Patients with Relapsed/Refractory Multiple Myeloma after Daratumumab Treatment: Real-World Findings from a Pooled Data Analysis of Preamble and the Mckesson Electronic Medical Record Database. Blood, 2018, 132, 3284-3284.	0.6	1
135	Absence of Plasma Gastric Biomarker Elevations with Chronic Dosing of Avatrombopag, a Novel Oral Thrombopoietin Receptor Agonist, in Patients with Chronic Immune Thrombocytopenia in Phase 3 Trials. Blood, 2018, 132, 3740-3740.	0.6	1
136	Phase 2 Study of Efgartigimod, a Novel FcRn Antagonist, in Adult Patients with Primary Immune Thrombocytopenia. Blood, 2019, 134, 895-895.	0.6	1
137	The Identification of Hypercoagulable Markers in Patients with Malignant Gliomas and Venous Thromboembolism Blood, 2006, 108, 4097-4097.	0.6	1
138	Patient Quality of Life (QOL) In Nonsplenectomized Immune Thrombocytopenia (ITP) Patients Receiving Romiplostim or Medical Standard of Care (SOC). Blood, 2010, 116, 569-569.	0.6	1
139	An Ongoing Multinational Observational Study in Multiple Myeloma (PREAMBLE): Preliminary Report on Patient Survival. Blood, 2015, 126, 2093-2093.	0.6	1
140	Markers of Autoimmunity in Immune Thrombocytopenia: Prevalence and Prognostic Significance. Blood, 2016, 128, 1363-1363.	0.6	1
141	Key Presenting Signs and Patient Co-Variables in Early Diagnosis of Type 3 Gaucher Disease: A Global Delphi Consensus Initiative. Blood, 2016, 128, 4886-4886.	0.6	1
142	Health care resource utilization (HCRU) in relapsed/refractory multiple myeloma (RRMM): Results from PREAMBLE Journal of Clinical Oncology, 2016, 34, 6621-6621.	0.8	1
143	Thrombopoietin Level Predicts Response to Treatment with Eltrombopag and Romiplostim in Immune Thrombocytopenia. Blood, 2018, 132, 734-734.	0.6	1
144	Sars-Cov-2 Vaccination in Patients with Pre-Existing Immune Thrombocytopenia. Blood, 2021, 138, 586-586.	0.6	1

#	Article	IF	CITATIONS
145	Quantitative analysis of desmopressin (DDAVP) response in adult patients with type 1 von Willebrand disease. International Journal of Laboratory Hematology, 2019, 41, 325-330.	0.7	0
146	Long-Term Follow-Up of Monoclonal Gammopathies in Gaucher Disease Patients on Enzyme Replacement Therapy Blood, 2006, 108, 3336-3336.	0.6	0
147	Gestational Platelet Trends and Outcomes in Women with Myeloproliferative Disorders Characterized by Thrombocytosis. Blood, 2008, 112, 5251-5251.	0.6	0
148	The Effects of Romiplostim or Standard of Care (SOC) on Splenectomy and Treatment Failure of Patients Who Had Immune Thrombocytopenia (ITP) for Less Than or Equal to One Year Blood, 2010, 116, 3702-3702.	0.6	0
149	Thrombin Generation During Abdominal Surgical Procedures: Effect of Prophylactic Anticoagulation Therapy. Blood, 2010, 116, 3183-3183.	0.6	0
150	Patient Reported Outcomes Comparison of Chronic Immune Thrombocytopenia (ITP) Patients Switched to Promacta and Nplate. Blood, 2011, 118, 2220-2220.	0.6	0
151	Miglustat Therapy in Type 1 Gaucher Disease: Long-Term Treatment Experience From a Multicenter, Retrospective Cohort Study,. Blood, 2011, 118, 3207-3207.	0.6	0
152	A Double-Blind, Placebo-Controlled, and Multiple Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ono-7746 in Healthy Subjects. Blood, 2011, 118, 4828-4828.	0.6	0
153	Single Oral Doses of a Novel Thrombopoietin Mimetic ONO-7746 Increase Platelet Counts In Healthy Subjects. Blood, 2011, 118, 4827-4827.	0.6	0
154	Romiplostim in Management of the Thrombocytopenic Surgical Patient. Blood, 2014, 124, 1459-1459.	0.6	0
155	A Global Delphi Consensus Initiative for Early Diagnosis of Gaucher Disease: Key Presenting Signs and Patient Co-Variables in Type 1 Disease. Blood, 2016, 128, 3676-3676.	0.6	0
156	A Global Delphi Consensus Initiative for Early Diagnosis of Gaucher Disease: Barriers, Their Resolution and the Impact on Patients. Blood, 2016, 128, 4885-4885.	0.6	0
157	FF-10102-01: A Novel, Highly Selective Spleen Tyrosine Kinase Inhibitor, to Be in Clinical Application for Treatment of Autoimmune Diseases and B-Cell Malignancies. Blood, 2016, 128, 3745-3745.	0.6	0
158	Survival in Patients with Relapsed/Refractory Multiple Myeloma: Outcomes after 4 Years of the Ongoing Multinational Observational Preamble Study. Blood, 2018, 132, 3285-3285.	0.6	0
159	Open-Label, Expanded Access Study of Taliglucerase Alfa in Patients with Gaucher Disease Requiring Enzyme Replacement Therapy. Blood, 2018, 132, 3755-3755.	0.6	0
160	Systemic Bevacizumab for the Treatment of Chronic Bleeding in Hereditary Hemorrhagic Telangiectasia. Blood, 2018, 132, 852-852.	0.6	0
161	An International Multicenter Study of Intravenous Bevacizumab for the Treatment of Chronic Bleeding and Anemia in Hereditary Hemorrhagic Telangiectasia: The Inhibit-Bleed Study. Blood, 2019, 134, 1060-1060.	0.6	0
162	Trial in Progress: Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Global Study of Fostamatinib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia. Blood, 2019, 134, 4800-4800.	0.6	0

#	Article	IF	CITATIONS
163	Thrombopoietin Level Predicts Response to Treatment with Romiplostim in Chemotherapy-Induced Thrombocytopenia. Blood, 2021, 138, 584-584.	0.6	Ο
164	Efficacy and Safety of Intravenous Efgartigimod 10 Mg/Kg in Adult Patients with Primary Immune Thrombocytopenia: Advance, a Phase 3 Clinical Trial in Progress. Blood, 2020, 136, 6-7.	0.6	0
165	Administration of Neuraxial Anesthesia in Adults with Pre-Existing Bleeding Disorders and Tendencies: Methodology for Delphi Consensus Recommendations. Blood, 2020, 136, 29-29.	0.6	Ο
166	Evaluation of the Prothrombin Fragment 1.2 in Patients with COVID-19. Blood, 2020, 136, 4-5.	0.6	0